Dow Jones Industrial Average 16,103.30 (Down) Week ending 02-21-2014
I am familiar with Salix Pharmaceuticals (Symbol SLXP, $105.37) for two reasons. I had started watching Salix when the stock was trading at 14 dollars per share and it went up to 21 and so I thought it was too expensive, so then I forgot about it and lost track of it. Secondly, I owned the stock of Santarus, which I had talked about on this blog earlier in an article last year and a couple of months ago Salix Pharmaceuticals came in and bought them out. So this time I am paying attention to SLXP.
Now let's go over the numbers that make it so attractive. First, the Current ratio on the stock is 4.3 to 1. The current market capitalization of the company is $6.63 Billion so it is a Mid-Cap stock. (I started this blog on Sunday last, so things are in motion). The company has annual revenues of $874.4 Million dollars. 2014 Revenues are projected at $1.59 Billion dollars.
This Raleigh, NC company has a One year stock price appreciation of 113.43% for the trailing 12 months. The company has 1 year earnings growth of 73.1%.
On my key benchmarks, the company has a PEG Ratio of 1.19 and a Return on Equity of 17.90%. A double pass on my checkoff list. The IBD rating on the stock for earnings is 93.
2013 earnings were $3.23 per share and for 2014 is projecting out at $6.04 per share. This is a forward PE of 16.94. The company operates at gross margins of 81.99 %.
Analyst Rankings on the stock are 7 Buy - 1 Outperform and 4 - Hold ratings. Hedge fund managers Joel Greenblatt and George Soros have been active trading the stock over the last year.
I would look for a down day in the market to find an entry point on this one. Again, always buy in small and accumulate a position even if you only buy 10 shares at a time.
I think that this holding will work out well for you for growth as part of your Healthcare holdings segment of your diversified portfolio.
Have a good week and the sooner you invest, the better your odds are of accumulating wealth.
Freewilly
Julia Roberts - waiting for a dance partner |
Now let's go over the numbers that make it so attractive. First, the Current ratio on the stock is 4.3 to 1. The current market capitalization of the company is $6.63 Billion so it is a Mid-Cap stock. (I started this blog on Sunday last, so things are in motion). The company has annual revenues of $874.4 Million dollars. 2014 Revenues are projected at $1.59 Billion dollars.
This Raleigh, NC company has a One year stock price appreciation of 113.43% for the trailing 12 months. The company has 1 year earnings growth of 73.1%.
On my key benchmarks, the company has a PEG Ratio of 1.19 and a Return on Equity of 17.90%. A double pass on my checkoff list. The IBD rating on the stock for earnings is 93.
2013 earnings were $3.23 per share and for 2014 is projecting out at $6.04 per share. This is a forward PE of 16.94. The company operates at gross margins of 81.99 %.
Analyst Rankings on the stock are 7 Buy - 1 Outperform and 4 - Hold ratings. Hedge fund managers Joel Greenblatt and George Soros have been active trading the stock over the last year.
I would look for a down day in the market to find an entry point on this one. Again, always buy in small and accumulate a position even if you only buy 10 shares at a time.
I think that this holding will work out well for you for growth as part of your Healthcare holdings segment of your diversified portfolio.
Have a good week and the sooner you invest, the better your odds are of accumulating wealth.
Freewilly